Navigation Links
New Drug Delivery System to Improve Cancer Treatment
Date:3/16/2011

SYRACUSE, N.Y., March 16, 2011 /PRNewswire/ -- Scientists in Syracuse University's Chemistry Department have created a new drug delivery system expected to advance the effectiveness of cancer-killing drugs. It uses gold nanoparticles with attached DNA that binds to a proven anti-cancer drug, Doxorubicin or DOX.

Preliminary tests indicate this delivery device has the potential to significantly improve the results of cancer chemotherapy. DOX is currently used against cancers of the breast, bone marrow, thyroid, bladder, ovary, small cell lung and several others.

"The possibilities of this new system are really exciting," says SU Professor James C. Dabrowiak. "For example, it would be easy to add to the device molecules that have the ability to target cancer cells. Another possibility is using light excitation to release high concentrations of an anti-tumor drug directly within the tumor."

These and other upgrades could enable clinics to focus chemotherapy more tightly on cancer cells and reduce negative side effects on healthy cells in other parts of the body.

A key element of the new system is that the DNA attached to the gold particles is engineered specifically to bind to the DOX anti-tumor drug. Studies show that the DOX can be transferred by diffusion to a receptor DNA molecule.

The gold nanoparticles have an average diameter of only 15.5 nanometers or a few billionths of a meter. A single nanoparticle presents more than 100 DOX sites and that, when multiplied by millions of the particles, could create a massive and deadly assault on a tumor.

"We believe this work can bring significant gains in the effectiveness of chemotherapy treatments," says Mathew M. Maye, SU Assistant Professor of Chemistry and co-inventor of the delivery system. "We still have work to do but this advance opens a promising new field of investigation that can lead to important new clinical tools."

A key advantage of the new system is that the DOX anti-tumor drug is already accepted by the FDA. Other such drugs may be deployed using this system simply by engineering the DNA to bind to a different drug molecule.

The Syracuse laboratory is continuing investigations to check the toxicity of the system. They will also explore "smart" particles capable of attaching to cancer cells and responding to triggers that will activate drug release. Prior discoveries demonstrate that such nano-delivery systems may be within reach and could help deliver large payloads of anti-tumor drugs where needed.

Graphic: Attacking Cancer with Tiny Drug Carriers

http://www.ereleases.com/pic/Syracuse-gold-nano.jpg

The work of the Syracuse University team was published in a February 2011 issue of ChemComm, a publication of the Royal Society of Chemistry. For more information and access to explanatory graphics, call (315) 443-4601 / 443-2146 or e-mail jcdabrow@syr.edu / mmmaye@syr.eduFor information, contact: Prof. James C. Dabrowiak(315) 443-4601 jcdabrow@syr.edu-or-Prof. Mathew M. Maye(315) 443-2146 mmmaye@syr.eduThis press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Syracuse University Office of Technology Transfer and Industrial Development
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Spherics, Inc. Offers Once Daily Extended Release Formulation for Sustained and Stable Pramipexole Delivery
2. Spherics, Inc. Announces Sale of Novel Proprietary Bioadhesive Polymers and Oral Drug Delivery System
3. Targeting Metastatic Cancer From the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
4. CEL-SCI Takes Delivery of New Manufacturing Facility
5. Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care
6. MonoSol Rx and Midatech Group Enter Collaboration Agreement to Unite Nanoparticle and Thin Film Drug Delivery Technologies
7. Probiotic Delivery Technology Awarded Third International Patent
8. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
9. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
10. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
11. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... Arizona (PRWEB) , ... August ... ... proud to introduce the Fluidnatek® Electrospinning and Electrospraying ... electrospraying equipment scales from table-top equipment for the lab to fully automated ...
(Date:8/16/2017)... ... August 16, 2017 , ... While art and science are often thought of ... one might think. A Mesh Is Also a Snare, a group exhibition presented ... Center’s Esther Klein Gallery (EKG) on August 17 and run through September 30. An ...
(Date:8/16/2017)... MN (PRWEB) , ... August 16, 2017 , ... ... our third U.S. Food and Drug Administration (FDA) inspection at our Dilworth, MN ... No 483 was issued. This inspection was conducted as part of a routine ...
(Date:8/16/2017)... OXFORD, England , Aug. 16, 2017  Kingfisher Talent, ... search and leadership development, and Virdis Group, global executive search ... exclusive alliance that enables clients to leverage the expertise and ... "For our clients here in the Boston ... diverse population of leadership talent throughout the US, ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/30/2017)... March 30, 2017 Trends, opportunities and forecast ... behavioral), by technology (fingerprint, AFIS, iris recognition, facial recognition, ... others), by end use industry (government and law enforcement, ... and banking, and others), and by region ( ... Asia Pacific , and the Rest ...
Breaking Biology News(10 mins):